2. Signaling Pathways
  3. Anti-infection
  4. Penicillin-binding protein (PBP)
  5. Penicillin-binding protein (PBP) Inhibitor

Penicillin-binding protein (PBP) Inhibitor

Penicillin-binding protein (PBP) Inhibitors (4):

Cat. No. Product Name Effect Purity
  • HY-B1286
    Piperacillin sodium
    		Inhibitor 98.01%
    Piperacillin sodium is a semisynthetic broad-spectrum β-lactam antibiotic which exhibits potent bactericidal activity against Gram-negative bacteria as well as select Gram-positive strains through penicillin-binding proteins. Piperacillin is most commonly used in combination with the β-lactamase inhibitor Tazobactam.
  • HY-B1286R
    Piperacillin sodium (Standard)
    		Inhibitor
    Piperacillin (sodium) (Standard) is the analytical standard of Piperacillin (sodium). This product is intended for research and analytical applications. Piperacillin sodium is a semisynthetic broad-spectrum β-lactam antibiotic which exhibits potent bactericidal activity against Gram-negative bacteria as well as select Gram-positive strains through penicillin-binding proteins. Piperacillin is most commonly used in combination with the β-lactamase inhibitor Tazobactam.
  • HY-117736
    Ro 09-1428
    		Inhibitor
    Ro 09-1428 is a broad-spectrum parenteral cephalosporin. Ro 09-1428 has potent antibacterial activities against Pseudomonas aeruginosa and Acinetobacter caloaceticus, with MIC90s of 0.39 and 6.25 μg/mL, respectively, better than Ceftazidime (HY-B0593). Additionally, Ro 09-1428 shows high activity against Escherichia coli, Kkbsielia pneumoniae, Proteus mirabilis, P. aeruginosa, staphylococci, and more. Ro 09-1428 preferentially attacks PBP 3 for target in E. coli and P. aeruginosa, which is promising for research of septicemias and serious P. aeruginosa infections.
  • HY-120366
    WCK-5153
    		Inhibitor
    WCK-5153 is a Penicillin-Binding Protein 2 (PBP2) inhibitor with an IC50 of 0.14 μg/ml (for P. aeruginosa PBP2) and acts as a β-lactam enhancer against Pseudomonas aeruginosa. WCK-5153 can be used in studies of multidrug-resistant (MDR) pathogens.